



9P 1743#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 2056 DALTONS

SERIAL NUMBER : 09/845,736

FILING DATE : 04/30/01

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1743

ATTORNEY DOCKET NO. : 2132.049

RECEIVED

DEC 11 2002

TC 1700 MAIL ROOM

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 12-2-02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

- Supplemental Information Disclosure Statement
- Certification Pursuant to 37 C.F.R. §1.97(e)
- Copy of International Search Report
- PTO-1449
- References

Respectfully Submitted,

Date: 12/2/2002

Ferris H. Lander
Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 2056 DALTONS

SERIAL NUMBER : 09/845,736

FILING DATE : 04/30/01

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1743

ATTORNEY DOCKET NO. : 2132.049

RECEIVED
DEC 11 2002
TC 1700 MAIL ROOM

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 12/2/02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.


A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Date: 12/2/2002

Respectfully Submitted,

Ferris H. Lander
Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2132.049

APPLICATION NO.
09/845,736

APPLICANT
JACKOWSKI et al.

FILING DATE
04/30/01

GROUP
1743

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

RECEIVED
DEC 11 2002
TOMO MAIL ROOM

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5,538,897	07/96	Yates, III et al.				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	WO 87/06344	10/87	PCT			X	
	WO 91/13352	09/91	PCT			X	
	WO 98/23290	07/98	PCT			X	
	WO 01/05422	01/01	PCT				X
	WO 00/49410	08/00	PCT			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Tang, et al., "Contribution of Renal Secreted Completed C3 to the Circulating Pool in Humans", Journal of Immunology (1999), Vol. 162, No. 7, pp. 4336-4341.
		Koch, et al., "A Novel Polymorphism of Human Complement Component C3 Detected by Means of a Monoclonal Antibody", Immunogenetics (1986), Vol. 23, No. 5, pp. 322-325.
		Harrison et al., "Structure of C3f, a Small Peptide Specifically Released during Inactivation of the Third Component of Complement", Component (1988), Vol. 5, No. 1, pp. 27-32.
		Agarwal, et al., "Immunologic Parameters in Infective Endocarditis: A Prospective Study", Indian Heart Journal (1991-05), Vol. 43, No. 3, pp. 179-183.
		Kristensen, et al., "Association Between Coronary Heart Disease and the C3 ^F -Gene in Essential Hypertension", Circulation (1978), Vol. 58, No. 4, pp. 622-625.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.